Specialist pharmaceutical company, Ambrose Healthcare Ltd (Ambrose Healthcare), whose ambitious plans to address ‘market pull’ and provide treatments for rare diseases, along with the unmet medical needs of patients managed in a hospital or specialist care setting, announces today that the world renowned Medical Key Opinion Leader Professor Brian Feagan is to advise the company on its rare disease and hospital drug product development.
Ambrose’s engagement with Professor Feagan will support clarification of the unmet patient needs, clinical development of its drug products and delivery of new treatments for rare diseases and unmet clinical needs of patients managed in hospital and specialist care environments.
Commenting, Professor Feagan said: ”In their previous company I worked with Toby and his team developing clinical trial plans, supporting interactions with regulatory agencies and executing international clinical trials as they develop their drug pipeline. Their standards of professionalism and delivery were exemplary, and I am looking forward to supporting them again with their exciting new venture.”
Toby Wilson Waterworth, Founder and Chair of Ambrose Healthcare, commented: “We are delighted to be working with Professor Feagan again. Brian has pioneered thought processes and understanding of clinical development in a number of rare disease and other therapeutic areas, and we are looking forward to interacting with Brian and benefiting from his input and guidance.”
About Professor Brian Feagan
Professor Dr Brian Feagan, M.D. is a Gastroenterologist, Professor of Medicine in the Departments of Medicine, and Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, a gastroenterologist at London Health Sciences Centre and Senior Scientific Director of Alimentiv Inc (formerly Robarts Clinical Trials Inc).
His research focus has been devoted to the development, validation and optimization of outcome measures to assess the efficacy of novel therapeutics, including rare diseases, and the design, conduct and execution of large-scale randomized controlled trials.
Over the past 30 years, has been Principal Investigator in over 140 multi-center international clinical trials, and authored over 400 articles.
He is the recipient of the Senior Achievement Award from the Crohn’s & Colitis Foundation of America (CCFA), Dean’s Award of Excellence from the University of Western Ontario, and has been named by Expertscape as one of the five foremost experts in the world for Crohn’s disease.
About Ambrose Healthcare (www.ambrosehc.com)
Ambrose Healthcare Ltd is a specialist pharmaceutical company, with ambitious plans to address ‘market pull’ – the call from patient groups and the medical community – to provide treatments for rare diseases and the unmet medical needs of patients managed in a hospital or specialist care setting.
Whilst the NIH lists more than 7,000 rare diseases[1], FDA reports only 600 drug approvals to date in 2020[3]. Some 400 million people worldwide are affected by rare diseases[2].
The Ambrose Healthcare team is seeking to replicate the success of its previous venture, where, applying the same rare disease, hospital focused strategy, and receiving $50M of investment in equity and grants, it delivered a product portfolio independently valued at $500M (Top 4 Global Accountancy Firm).
Ambrose Healthcare, through acquisition, licencing and collaboration, is developing a portfolio of commercial and clinical stage therapeutic assets.
The company will commercialise its products in its core markets of the US, Europe, and the Middle East, and in other territories via licencing or distribution agreements with established pharmaceutical companies.
References:
1. U.S. National Institutes of Health (rarediseases.info.nih.gov/about)
2. CamRARE – Cambridge Rare Disease Network (www.camraredisease.org/)
3. National Organization for Rare Disorders (rarediseases.org/new-study-investigates-the-number-of-available-orphan-products-generics-and-biosimilars/
For more information, please contact:
Ambrose Healthcare
Adam Michael, Director of Communications
adam.michael@ambrosehc.com +44 7775 881 813
Prof. Dr Brian Feagan
Senior Scientific Director, Alimentiv Inc, Canada
brian.feagan@alimentiv.com +1 (519) 663 3837